Welcome to our dedicated page for RxSight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RxSight, Inc. filings document the public-company record for a Nasdaq-listed ophthalmic medical device issuer centered on the RxSight Light Adjustable Lens system. Form 8-K reports furnish operating results, sales guidance, Light Adjustable Lens and Light Delivery Device commercial metrics, preliminary results and other material updates tied to financial condition.
The company’s proxy and governance filings cover annual meeting matters, board and committee composition, executive compensation, equity awards and stockholder voting procedures. Other current reports address officer appointments, transition agreements, compensatory arrangements and the registered common stock structure for RXST.
RxSight, Inc. (RXST) reported that Chief Medical Officer Ronald M. Kurtz, MD had 13,425 Restricted Stock Units vest on August 31, 2026, converting into 13,425 shares of common stock. On the same date, he continued to hold 67,120 RSUs directly. On September 2, 2026, 5,100 common shares were sold at $6.96 per share to satisfy tax withholding obligations related to this RSU vesting, which the company notes did not represent a discretionary sale. Separately, 764,610 common shares are held indirectly through Cricklewood LP, an entity over which Dr. Kurtz shares voting and investment control with his spouse.
RxSight, Inc. (RXST) reported that Chief Financial Officer Mark Wilterding had Restricted Stock Units vest and related share movements in late August 2026. On August 31, 2026, 20,441 RSUs, each representing a contingent right to one share of common stock, converted into 20,441 common shares, leaving him with 122,646 shares held directly after this derivative transaction. On September 2, 2026, he sold 7,765 common shares at $6.96 per share to cover tax withholding obligations arising from the RSU vesting, which the company states did not represent a discretionary sale. No Rule 10b5-1 trading plan is reported.
RxSight, Inc. (RXST) Chief Operating Officer Ilya Goldshleger reported transactions involving Common Stock and Restricted Stock Units. On August 31, 2026, RSUs representing 5,370 shares converted into Common Stock, resulting in 26,848 shares held directly. On September 2, 2026, 2,041 shares of Common Stock were sold at $6.96 per share to cover tax withholding obligations related to RSU vesting, which the company states was not a discretionary sale. Goldshleger also reports indirect ownership of 1,372 shares held by his spouse. No transactions are reported under a Rule 10b5-1 trading plan.
RxSight, Inc. (RXST) reported that Chief Business Development Officer Eric Weinberg had restricted stock units convert into 5,370 shares of Common Stock on August 31, 2026, with no exercise price, and that 2,041 shares of Common Stock were sold on September 2, 2026 at $6.96 per share. According to the company, the 2,041 shares sold "represent the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale" by Weinberg, and no Rule 10b5-1 trading plan is reported. After these events, Weinberg continues to hold Common Stock indirectly through the EJW Living Trust and his spouse, and retains a significant RSU position scheduled to vest in six installments between August 31, 2026 and February 28, 2029, subject to his continued service.
RxSight, Inc. (RXST) amended its previously announced employee option exchange program. The company is conducting an Exchange Offer allowing certain eligible employees to exchange some or all of their outstanding stock options for new equity awards, on terms described in an Offer to Exchange dated August 10, 2026.
This amendment primarily updates the list of related documents and materials, including launch and reminder communications, website screenshots, and employee presentations, and ties the program to the company’s 2021 Equity Incentive Plan. The amendment does not change the core structure of the Exchange Offer itself.
RxSight, Inc. (RXST) is reported to have a significant shareholder group led by Point72. Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen jointly report beneficial ownership of 2,487,468 shares of RxSight common stock, representing 6.0% of the class as of the close of business on August 18, 2026.
The reporting persons have shared voting and dispositive power over 2,487,468 shares and no sole voting or dispositive power. The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, which has investment and voting power under an investment management agreement. The filing states it should not be construed as an admission that any reporting person is the beneficial owner for Section 13 purposes.
RxSight, Inc. (RXST) received a notice under Rule 144 that former director Raymond W. Cohen intends to sell 11,890 shares of common stock. The proposed sale, with an indicated value of $75,748.81, is to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
RxSight, Inc. has launched an employee stock option exchange offer covering up to 4,083,693 options granted under its 2021 Equity Incentive Plan. Eligible options are those, vested or unvested, with per-share exercise prices at or above $6.00 for most employees and $10.00 for named executive officers, and at or above the closing stock price on the offer’s expiration date.
Eligible employees are U.S.-based employees, including named executive officers, who remain employed through the offer’s expiration and the new award grant date. Non-U.S. employees and non-employee directors cannot participate. Non-executive employees may exchange eligible options for restricted stock units, while named executive officers may exchange for new stock options, under the terms and conditions described in the company’s offer materials.
RxSight, Inc. reported Q2 2026 revenue of $33,741 (amounts in thousands of dollars), compared with $33,637 a year earlier. Product sales declined to $27,241, while license and collaboration revenue of $6,500 from a new Alcon agreement offset much of that change. Q2 net loss was $12,097, or $0.29 per share.
For the first six months of 2026, revenue was $64,634 and net loss $27,981, with operating cash outflows of $20,429 (all in thousands). Liquidity remained strong with $208.8 million in cash, cash equivalents and short‑term investments. RxSight ended June with 1,166 installed Light Delivery Devices and approximately 357,000 cumulative Light Adjustable Lens implants.
The Alcon collaboration includes a $60 million upfront payment, of which $10.0 million is the initial transaction price, with $6.5 million recognized as license revenue and $3.5 million deferred. The remaining $50.0 million is refundable within 120 days. Alcon may also owe $70 million, $30 million and $40 million milestones plus 30% royalties on Collaboration Product net sales.
RxSight, Inc. reported second-quarter 2026 revenue of $33.7 million, including $6.5 million from its strategic collaboration with Alcon and $27.2 million of product sales. Product sales declined 19% from a year earlier, reflecting competitive trialing and softer consumer sentiment, and included 24,917 Light Adjustable Lens units and 12 Light Delivery Devices.
Excluding collaboration revenue, gross margin was 71.2% versus 74.9% a year ago; including it, gross margin was 76.7%. Operating expenses were $39.7 million, and the company posted a net loss of $12.1 million, or $0.29 per share, with adjusted net loss of $4.6 million, or $0.11 per share. Cash, cash equivalents and short-term investments totaled $208.8 million as of June 30, 2026.
RxSight appointed Aziz Mottiwala as President and Chief Executive Officer, entered a strategic collaboration with Alcon featuring up to $200 million in potential upfront and milestone payments plus future royalties, and advanced next-generation Light Adjustable Lens technologies. In connection with the leadership transition, it withdrew 2026 guidance and plans to resume formal guidance in early 2027.